A related concept that highlights the advantage of nanobodies as complement-activating tumor therapeutics has recently been described by Pedersen et al. In their work, they developed a bispecific complement engager (BiCE) that induced CDC against CD38-expressing tumor cells52. This evidence concerns the gene CD38 and neoplasm.